RxDoctor Payments Data

Angela Peterson

Family · Rexburg, IDNPI 1851916365

Payments from drug & device makers

$2,511in general payments, 2019–2025

Across 133 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Axsome Therapeutics, Inc.$330
  • Novo Nordisk$179
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$164
  • Lilly USA, LLC$150
  • Vanda Pharmaceuticals Inc.$132
  • plus $947 from 25 others

What the payments were for

  • Food & beverage$2,499100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,511 in reported general payments places this provider in the 85th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$24,698
Medicare patients
136
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$34,020
MounjaroTirzepatide27$27,469
EliquisApixaban39$26,002
VraylarCariprazine Hcl17$23,242
GemtesaVibegron25$13,599
FarxigaDapagliflozin Propanediol18$12,656
TrulicityDulaglutide11$12,585
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,407
Lurasidone Hcl19$7,517
Methylphenidate ErMethylphenidate Hcl18$6,560
Trijardy XrEmpaglifloz/Linaglip/Metformin11$6,439
Pregabalin60$4,922
Aripiprazole16$4,911
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine59$4,063
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen77$2,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$150$40,05438 claims
Novo NordiskOzempic$179$34,02035 claims
PfizerEliquis$13$26,00239 claims
AbbVieVraylar$610$23,24217 claims
Sumitomo Pharma America, Inc.Gemtesa$4$13,59925 claims
GSKTrelegy Ellipta$99$12,40716 claims
Boehringer IngelheimTrijardy Xr$14$6,43911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Idaho.

Other family in Rexburg

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →